Adma Biologics reported $75.63M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Adma Biologics USD 75.63M 8.4M Sep/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
Minerva Neurosciences -4.27M 26.79M Dec/2024
Novavax USD 23.89M 239.21M Sep/2024
Omeros USD -33.16M 18.52M Jun/2024
Takeda JPY 790.55B 262.97B Dec/2025